ArticleGenes and immunity2026
Potential role of Akkermansia massiliensis in multiple sclerosis protection by the FcRL3 gene.
Article in Genes and immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The contribution of human genetics in shaping the abundance of gut microbiota is small, about 5%; however, it can inform about disease etiopathogenesis, including multiple sclerosis (MS). Searching for MS-gut microbiota cross-comparison of reported genome-wide association studies (GWAS), we identified a coincident association of the disease with a commensal - Akkermansia massiliensis-in the selective Fc receptor of secretory IgA gene (FcRL3). Those two signals colocalized, supporting that lower abundance of A.massiliensis may contribute to MS predisposition. In cis, the FcRL3-MS predisposing signal downregulates the FcRL3 protein production and modulates the dynamic intron usage between naïve and mature B-cells, which we believe to be the primary molecular mechanism associated with MS risk in this region. The signal also increases the expression of the FcRL5 gene. In trans, it reduces the expression of neuropeptide B/W receptor 1 (NPBWR1) and azurocidin (AZU1), whereas it increases the expression of the tumor necrosis factor receptor superfamily, member 13B (TACI). Our view of MS etiopathogenesis suggests that low levels of FcRL3 and A. massiliensis may predispose to MS by causing impaired self-tolerance to commensal microbiota, dysregulation of B-cell function, and immune system effects on the neuroendocrine signaling by AZU1 and NPBWR1 proteins, which may be further investigated as targets for MS.
Indexed as
Identifiers
42436285What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.